By Chris Wack
Phio Pharmaceuticals shares more than tripled after the company said it saw positive results from its Phase 1b trial for its cancer treatment PH-762.
Shares were recently up more than 270% to $6.30 in mid-morning trading after earlier hitting a session high of $6.49.
The biotechnology company said it had positive pathologic responses for patients enrolled in the second cohort of the trial, which includes two patients with a complete response or 100% tumor clearance.
Phio's ongoing Phase 1b clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoralPH-762 in cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Of the patients enrolled to date, six patients were diagnosed with cutaneous squamous cell carcinoma and one patient was diagnosed with metastatic melanoma.
There have been no dose-limiting toxicities, or clinically relevant treatment-emergent adverse events in the patients receiving intratumoral PH-762, said the company. The intratumoral injections have been well tolerated, Phio added.
Phio stock hit its 52-week low of $1.53 on Dec. 19, and is down about 2% in the past 12 months.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 13, 2025 10:08 ET (15:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。